Sunday 11 October 2026 Export all GILD data to Excel Powerpack

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

151.17 4.07 +2.77%
Market cap
$182.4B
P/E
0.0×
Fwd P/E
−46.2×
Dividend yield
2.15%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100

Gilead Sciences, Inc. 10-Q filed Aug 6, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:13 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 7, 2026: 33 added · 8 removed · 31 modified; 5 with only figures updated

  1. Modified

    The following discussion and analysis is intended to provide material information around events and uncertainties known to management that are relevant to an assessment of the financial condition and results of operations of Gilead and should therefore be read in conjunction with our audited Consolidated Financial Statements and the related notes thereto and other disclosures included as part of our Annual Report on Form 10-K for the year ended December 31, 2025 and our unaudited Condensed Consolidated Financial Statements for the three and six months ended March 31June 30, 2026 and the related notes thereto and other disclosures (including the disclosures under Part II, Item 1A. Risk Factors) included in this Quarterly Report on Form 10-Q.

71 more changes in this Item, word by word, in Powerpack.

Powerpack